Benitec Biopharma to Participate in the Citizens JMP Life Science Conference
Rhea-AI Summary
Benitec Biopharma Inc. (BNTC) will participate in the Citizens JMP Life Science Conference in New York on May 13-14, 2024, presenting its gene therapy-focused ddRNAi platform. The presentation by Jerel Banks, MD, PhD, Executive Chairman and CEO, will be webcasted live.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, BNTC declined 6.51%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
HAYWARD, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that members of Benitec management will participate in Citizens JMP Life Science Conference, taking place in New York, NY from May 13-14, 2024.
Presentation Details:
Date: May 13, 2024
Time: 11:00 am EDT
Presenter: Jerel Banks, MD, PhD, Executive Chairman and Chief Executive Officer
The Benitec presentation will also be available via live webcast here.
Please contact your Citizens JMP representative to schedule a 1x1 meeting with Benitec management.
About Benitec Biopharma Inc.
Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.
Investor Relations Contact:
Irina Koffler
LifeSci Advisors
Tel: (917) 734-7387
ikoffler@lifesciadvisors.com
FAQ
When will Benitec Biopharma participate in the Citizens JMP Life Science Conference?
What is Benitec Biopharma's proprietary platform?
Who will be presenting at the conference from Benitec Biopharma?
How can I watch the Benitec Biopharma presentation?
How can I schedule a 1x1 meeting with Benitec management?
